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http://dxObjective: Enlargement of the aortic annulus may be required during aortic valve replacement to avoid patient–
prosthesis mismatch. We reviewed patients with enlargement of the aortic annulus with the aim of assessing the
stability of the procedure by means of echocardiographic and angio–computed tomography studies.
Methods: A series of 53 consecutive patients underwent aortic valve replacement and enlargement of the aortic
annulus from 1994 to 2012. The mean age was 68  11 years (range, 29-84 years), and 85% (45 patients) were
female. The predominant valvular lesion was aortic stenosis. The mean logistic European System for Cardiac
Operative Risk Evaluation was 11.2  13.0. Enlargement of the aortic annulus was performed by extending
the aortotomy incision to separate the commissure between the left and noncoronary sinuses into the anterior
mitral leaflet and closing the resulting defect with an adequately tailored patch of bovine pericardium.
Results: Hospital mortality was 2%, with 20 late deaths mostly due to noncardiac causes. At a maximum follow-
up of 18 years (mean, 8.9 5.0 years), actuarial survival is 37% 9%. No cases of severe patient–prosthesis mis-
matchwere observed, and only 2 patients hadmoderate patient–prosthesismismatch.At discharge, themean aortic
root diameter was 30.0 2.3mmand themean diameter at the sinotubular junctionwas 31.5 5.0mm.At follow-
up, the mean aortic root diameter was 31.0  3.4 mm and the mean diameter at the sinotubular junction was
31.7  4.5 mm (P ¼ not significant) with no cases of late aneurysm formation on angio–computed tomography.
Conclusions: Enlargement of the aortic annulus is a safe and effective procedure and should be indicated in pa-
tients with a small aortic annulus; particularly, it should be considered to prevent patient–prosthesis mismatch
and its potential deleterious long-term effects. (J Thorac Cardiovasc Surg 2014;147:977-83)A
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DEnlargement of the aortic annulus (EAA) may be required
during aortic valve replacement (AVR) to insert a prosthesis
of adequate size and avoid potential patient–prosthesis mis-
match (PPM).1 Although techniques to perform EAAwere
introduced more than 4 decades ago,2-5 little is known about
the long-term results with particular regard to the late
changes in aortic root dimensions and whether pericardial
patches, when used in such procedures, may be prone to an-
eurysmal dilatation over time. We review our experience
with a series of patients undergoing EAA at the time of
AVR using patches of bovine pericardium and verify the
long-term follow-up stability of this procedure by means
of echocardiographic and angio–computed tomography
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The Journal of Thoracic and CaMATERIALS AND METHODS
From August 1994 to December 2009, 2248 patients underwent AVR;
concomitant EAAwas performed in 53 (2.4%) of these patients, and they
form the basis of this report, representing the entire subset of patients having
EAAduring this time interval. This retrospective studywas approved by the
ethics committee of University Hospital of Pisa, Italy. All patients were in-
formed of the nature of the study, which included clinical, echocardio-
graphic, and ACT examinations, and gave their consent to participate,
allowing collection and analysis of their clinical and follow-up data.
Surgical Technique
The technique of aortic annulus enlargement routinely used in University
Hospital of Pisa, Italy, has been described6,7 and is similar to that proposed by
Nunez and colleagues8 in 1983. The operation is performed through amedian
sternotomy with standard cardiopulmonary bypass and moderate systemic
hypothermia, topical cooling, and antegrade cold blood cardioplegia. After
aortic crossclamping, a transverse aortotomy is performed and the aortic
valve is excised with debridement of the annulus, which is measured with
commercially available sizers. In the presence of a diminutive aortic annulus
(19 mm), EAAwas considered indicated on the basis of patient’s body sur-
face area (BSA).More recently, avoidance of PPM has been based on the cri-
teria defined by Pibarot and Dumesnil.9 For EAA, the aortotomy is carried
down through the commissure between the left and noncoronary sinuses
into the interleaflet triangle and anterior mitral leaflet. The extension of the
incision depends on the patient’s anatomy and the surgeon’s judgment; how-
ever, in any case, opening the roof of the left atrium is carefully avoided. The
incision is then closed using a teardrop-shaped patch of pericardium, with
a maximal width of approximately 2 cm, sutured with a continuous suture
of 4-0 polypropylene starting at the nadir of the incision. In the present series,rdiovascular Surgery c Volume 147, Number 3 977
Abbreviations and Acronyms
ACT ¼ angio–computed tomography
AVR ¼ aortic valve replacement
BSA ¼ body surface area
EAA ¼ enlargement of the aortic annulus
iEOA ¼ indexed effective orifice area
LV ¼ left ventricular
NYHA ¼ New York Heart Association
PPM ¼ patient–prosthesis mismatch
STJ ¼ sinotubular junction
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aortic annulus is enlarged on the basis of the width of the pericardial patch.
Both mechanical and bioprosthetic valves were implanted using multiple su-
tures of 2-0 Ethibond (Ethicon Ltd, Livingston, Scotland) reinforced by Tef-
lon felts placed in the subannular position. At the level of the pericardial
patch, sutures were passed from outside to inside leaving the pledgets exter-
nally. After the prosthesis was seated and the sutures were tied, the aortotomy
was closed using the pericardial patch, thus obtaining partial enlargement of
the aortic root. At the end of the procedure, fibrin glue was applied to the su-
tures to improve hemostasis. All patients were given subcutaneous calcium
heparin or low-weight heparin postoperatively; oral anticoagulants were
started on postoperative day 1 or after extubation, and heparinwas suspended
when a target international normalized ratio of 2 to 3 was reached. Anticoag-
ulants were maintained indefinitely in patients with a mechanical prosthesis
and for only 3 months after AVR in those with a bioprosthesis, except in pa-
tients with chronic atrial fibrillation or other risk factors for thromboembolic
complications. However, since 2006, most patients having a tissue valve for
AVR receive only antiplatelet drugs.
Follow-up
After discharge, all patients were encouraged to refer to our outpatient
clinic for periodical evaluations,whichwere scheduled at 1, 3, and 6months
after surgery and on a yearly basis thereafter, to obtain information on their
clinical status and on the rate and type of any postoperative complications
that were defined using established guidelines.10 For patients whowere un-
able to come to the outpatient clinic, information was gathered from phone
interviews or by contacting relatives or referring physicians. The last
follow-up update was conducted during a 6-month interval ending in Sep-
tember 2012. The mean duration of follow-up, which is 92% complete, is
8.9  5.0 years (range, 0.3-18 years). Four patients could not be traced.
Themean follow-up of late survivors is 10.8 5 years (range, 3.5-18 years).
Echocardiographic Controls
Because the primary end point of the study, in addition to patient sur-
vival and freedom frommajor valve-related events, was to verify the stabil-
ity of the repair at long-term follow-up, all long-term survivors underwent
a transthoracic 2-dimensional echocardiographic control examination at
University Hospital of Pisa, Italy. The goal was to assess late prosthetic per-
formance and overall cardiac function by evaluating mean and peak trans-
prosthetic gradients, effective orifice area, left ventricular (LV) ejection
fraction, LV diameters and volumes, and degree of LV hypertrophy by
means of the LV septal thickness. Aortic root diameters, taken at the levels
of the sinuses of Valsalva and the sinotubular junction (STJ), were com-
pared with those calculated at the time of discharge to exclude any evidence
of aortic root dilatation. The occurrence of PPM also was considered and
defined as mild when the indexed effective orifice area (iEOA) was 0.85
cm2/m2 or greater, moderate when iEAO was between 0.85cm2/m2 and
0.65 cm2/m2, and severe when iEAO was 0.65 cm2/m2 or less.978 The Journal of Thoracic and Cardiovascular SurgAngio–Computed Tomography Studies
An ACT evaluation was planned in patients without a contraindication
to administration of contrast material, and 9 of the long-term survivors
(32%) gave consent for such a study; 16 patients refused to undergo
the ACT study, and moderate renal failure was considered a contraindica-
tion to such an investigation in 3 patients. The result of ACT imaging pro-
vided further calculations of the aortic diameters that were compared
with those obtained at 2-dimensional echocardiography at last follow-
up. The presence and location of any aortic wall calcification were
assessed. ACT studies were carried out on a 64-row computed tomogra-
phy scanner (LightSpeed VCT; General Electric, Milwaukee, Wis) with
the following parameters: retrospective electrocardiographic gating, de-
tector configuration 64 3 0.625 mm, tube voltage 100 kV, tube current
150 to 500 mA (electrocardiographic-based current modulation with
peak current between 70% and 80% of the R-R interval), tube rotation
time 0.35 seconds, slice thickness 0.625 mm, reconstruction interval
0.625 mm, and standard convolution kernel. Each patient received 60
to 80 mL of nonionic iodinated contrast medium (iodixanol 320
mg/mL: Visipaque 320, GE Healthcare, Oslo, Norway) injected intrave-
nously at a flow rate of 4 to 5 mL/s, followed by 40 mL of saline chaser
administered at the same flow rate. Scanning was performed in the
cranio-caudal direction and spanned the entire thoracic aorta from ap-
proximately 2 cm above the origin of supra-aortic vessels to the lung ba-
ses. The start of each computed tomography acquisition was determined
by means of bolus tracking at the level of the aortic root using a density
threshold of 100 HU.
Statistical Analysis
Data are presented as mean  standard deviation and as simple per-
centages. The linearized rate of postoperative complications was ex-
pressed as percent per year (%/year)  standard error. Overall
survival was determined by Kaplan–Meier actuarial analysis and ex-
pressed as percentage  standard error. Student t test or Wilcoxon
test for continuous data and chi-square or Fisher test for discrete vari-
ables were used, as appropriate. Data analysis was performed by using
commercially available SPSS version 17.0 (SPSS, Inc, an IBM Com-
pany, Chicago, Ill).RESULTS
Patient Data
The most significant preoperative patient characteristics
are summarized in Table 1. Themean agewas 68 11 years
(range, 29-84 years), and 85% (45 patients) were female;
mean BSA was 1.68  0.15 cm2 (range, 1.40-2.10 cm2).
The predominant valvular lesion was aortic stenosis in 51
patients (96%) and aortic regurgitation in 2 patients
(4%); 46 patients (87%) were in sinus rhythm, and 7 pa-
tients (13%) were in chronic atrial fibrillation. Preopera-
tively, 10 patients (19%) were in functional class IV
according to the New York Heart Association (NYHA),
32 patients (60%) were in class III, and 11 (21%) patients
were in class II. The mean NYHA class was 3.0  0.7.
Cardiovascular risk factors, mainly hypertension and diabe-
tes, were present in 46 patients (87%); 1 patient (2%) was
on chronic hemodialysis. Associated cardiac pathologies
were observed in 19 patients, primarily coronary artery
disease (9 patients, 47%) and mitral valve disease (7
patients, 37%). The mean logistic European System for
Cardiac Operative Risk Evaluation was 11.2  13.2.ery c March 2014
TABLE 1. Summary of patient characteristics
Gender
Male 8 (15%)
Female 45 (85%)
Age (y)
Mean (SD) 68  11
Range 29-84
>80 6 (11%)
BSA (cm2)
Mean (SD) 1.68  0.15
Rhythm
Sinus 46 (87%)
AF 7 (13%)
NYHA class
I 0
II 11 (21%)
III 32 (60%)
IV 10 (19%)
Valvular lesion
Pure or prevalent stenosis 51 (96%)
Pure or prevalent incompetence 2 (4%)
Cause
Calcific degeneration 35 (66%)
Rheumatic 15 (28%)
Prosthesis failure 3 (6%)
Log euroSCORE
Mean (SD) 11.2  13.2
SD, Standard deviation; BSA, body surface area;NYHA,NewYork Heart Association;
euroSCORE, European System for Cardiac Operative Risk Evaluation; AF, atrial fi-
brillation.
TABLE 2. Operative data
Emergency 3 (6%)
Redo 6 (11%)
CPB time (min)
Mean  SD 122  43
ACC time (min)
Mean  SD 93  27
Prosthesis size
19 mm 3 (6%)
21 mm 36 (68%)
23 mm 14 (26%)
Prosthesis
Mechanical 31 (58%)
Biological 22 (42%)
Associated procedures
CABG 9 (17%)
MV surgery 7 (13%)
Other 4 (8%)
Operative mortality 1 (2%)
CPB, Cardiopulmonary bypass; SD, standard deviation; ACC, aortic crossclamp;
CABG, coronary artery bypass grafting; MV, mitral valve.
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Operative data are summarized in Table 2. AVR was per-
formed on an emergency basis in 3 patients (6%), and 6 pa-
tients (11%) underwent reoperation for dysfunction of
a previously implanted aortic (n¼ 3) or mitral (n¼ 3) pros-
thesis; previously implanted aortic prostheses were 19 mm
in 2 patients and 21 mm in 1 patient. Associated procedures
were performed in 20 patients (38%) and were mainly cor-
onary artery bypass grafting (9 patients) and mitral valve re-
placement or repair (7 patients). LV septal myectomy was
never performed. Mean aortic crossclamp time was
93  27 minutes (range, 50-201 minutes), and mean dura-
tion of cardiopulmonary bypass was 122  43 minutes
(range, 71-323 minutes). A mechanical prosthesis was im-
planted in 31 patients (58%), and a bioprosthesis was im-
planted in 22 patients (42%). Prosthetic sizes were 19
mm in 3 patients (6%), 21 mm in 36 patients (68%), and
23 mm in 14 patients (26%).
Early Mortality and Morbidity
Therewas 1 operative death (2%) due to cardiac failure 10
days after combined AVR and mitral valve replacement. In
this patient, a 19-mm mechanical prosthesis was inserted in
the aortic position with residual mild PPM. Intensive care
unit stay more than 72 hours was required in 10 patients
(19%), and prolonged mechanical ventilation (>96 hours)The Journal of Thoracic and Cawas required in 5 patients (9%).Major postoperative compli-
cations included transient atrial fibrillation in 20 patients
(38%), renal insufficiency in 3 patients (6%), and atrioven-
tricular block in 3 patients (6%). Mean drainage from the
chest tubeswas 621 357mL.Chest reexploration for bleed-
ing was required in 8 patients, but the cause of bleeding was
not at the aortotomy site in any of these patients. Patientswere
discharged 4 to 34 days after AVR (mean, 9.5  6.0 days).
Late Survival and Complications
There were 20 late deaths (40%). Causes of late deaths
were old age in 5 patients (25%), all of whom were aged
more than 90 years at the time of death, neoplasms in 4
patients (20%), pulmonary embolism in 3 patients
(15%), cardiac failure in 2 patients (10%), stroke in 2
patients (10%), renal failure in 1 patient (5%), hepatic
failure in 1 patient (5%), and unknown in 2 patients
(10%). Actuarial survival is 68%  7% at 10 years and
37%  9% at 15 and 18 years (Figure 1). At last
follow-up, 17 patients (60%) are in NYHA class I and
11 patients (40%) are in class II with a mean NYHA class
of 1.43  0.5 (P< .05).
Thromboembolic complications occurred in 2 patients 8
and 14 years after AVR with a mechanical prosthesis; both
sustained a fatal stroke. Linearized incidence of thrombo-
embolic complications is 0.42%  0.30% patient-years.
Endocarditis was observed 2 years after AVR in 1 patient
who died at reoperation with a linearized incidence of
0.21%  0.21% patient-years. Another patient underwent
successful reoperation after 8 years for dysfunction of a mi-
tral prosthesis implanted at the time of AVR. Linearized
incidence of reoperation (2 patients) is 0.42%  0.30%
patient-years.rdiovascular Surgery c Volume 147, Number 3 979
FIGURE 1. Actuarial survival after aortic valve replacement with en-
largement of the aortic annulus.Numbers on the horizontal axis indicate pa-
tients at risk.
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Preoperative 2-dimensional echocardiography showed
a mean LVejection fraction of 55% 7%. The mean thick-
ness of the LV septum was 12.3  1.4 mm. The peak and
mean transvalvular gradients were 91  20 mm Hg and
56  11 mm Hg, respectively. The mean aortic annulus di-
ameter was 19.4  1.0 mm. The mean aortic root diameter,
at the level of the sinuses of Valsalva, was 27.6  2.5 mm.
The mean ascending aorta diameter, at the level of the STJ,
was 30.7  5.0 mm. Other preoperative echocardiographic
parameters are shown in Table 3.
At discharge, mean LVejection fraction was 52% 4%,
LV septum thickness was 12.1  0.8 mm, peak transpros-
thetic gradient was 25  10 mm Hg, mean transprosthetic
gradient was 15  6 mm Hg, and iEOA was 0.91  0.23
cm2/m2. The mean aortic root diameter was 29.9  2.7
mm, and the mean diameter at the STJ was 31.2  6.1 mm.
At latest follow-up, LVejection fraction was 54% 5%,
LV septum thickness was 10.8  1.2 mm, peak transpros-
thetic gradient was 24  10 mm Hg, mean transprosthetic
gradient was 14  6 mm Hg, and iEOA was 0.88  0.20
cm2/m2. The mean aortic root diameter was 31.1  3.7
mm, and the mean diameter at the STJ was 31.2  5.3
mm. For valve sizes in patients with 19-mm prostheses,
the peak transprosthetic gradient was 18  10 mm Hg,
mean transprosthetic gradient was 11  6 mm Hg, and
iEOA was 0.77  0.18 cm2/m2. In patients with a 21-mm
prosthesis, the peak transprosthetic gradient was 26  10
mm Hg, mean transprosthetic gradient was 15  7 mm
Hg, and iEOA was 0.91  0.21 cm2/m2. In patients with
a 23-mm prosthesis, peak transprosthetic gradient was
18  4 mm Hg, mean transprosthetic gradient was 11  2
mm Hg, and iEOAwas 1.02  0.34 cm2/m2.
A significant difference was found between the LV wall
thickness and the aortic root diameter at follow-up when980 The Journal of Thoracic and Cardiovascular Surgcompared with preoperative and discharge values (P<.05
and P<.001, respectively) and between transprosthetic gra-
dients at discharge and follow-up when compared with pre-
operative values (P < .001). Finally, no cases of
periprosthetic leak were observed, but 3 patients had mild
mitral insufficiency.
Angio–Computed Tomography Data
An ACT study was performed in 9 patients at latest
follow-up. Patient age ranged from 35 to 86 years at the
time of the study (mean, 67  15 years); ACT was per-
formed 3 to 17 years from AVR (mean, 10.7  5.0 years).
Mean aortic root diameter was 29.7  5.8 mm, and mean
diameter at the STJ was 29.0  6.5 mm, with no significant
difference with corresponding diameters at echocardiogra-
phy (P¼ not significant). Diffuse calcifications of the aorta
were observed in 2 patients (aged 84 and 86 years). Calcific
spots mainly on the ascending aorta and arch were present
in 6 patients, but no calcifications were seen in 1 patient
(aged 35 years). Calcifications corresponding to the site of
the pericardial patch were identified in 4 patients (Figure 2).
Evaluation of Patient–Prosthesis Mismatch
According to intraoperative measurements, the aortic an-
nulus size ranged from 17 to 21 mm (mean, 18.7  0.6).
The mean size of implanted prostheses was 21.4  1.0
mm, yielding a size gain of 1.36  0.5 mm. A prosthesis 1
size larger was implanted in 17 patients and 2 sizes larger
was implanted in 19 patients. Moderate PPM was observed
in 2 patients, with a 19-mm mechanical prosthesis. In all
other patients, the iEOAwas more than 0.85 cm2/m2 (mean
iEOA, 0.91  0.2 cm2/m2 at discharge and 0.88  0.2 cm2/
m2 at follow-up) (Table 3). Had the prosthetic size been se-
lected simply on the basis of intraoperative measurements,
by implanting the prosthesis that would have fitted the mea-
sured annulus, this would have caused moderate PPM in all
patients. The iEOA of the implanted prostheses would have
been 0.74  1.4 cm2/m2, which is significantly different
from that actually obtained (0.91  0.2 cm2/m2) after EAA.
DISCUSSION
In patients with calcific aortic stenosis, the main goals of
AVR are relief from LV obstruction and avoidance of PPM
by implanting a prosthesis of adequate size. Although the
concept of PPM introduced by Rahimtoola1 more than 40
years ago is currently well recognized, the impact of PPM
on late survival after AVR is still controversial. Nevertheless,
although satisfactory hemodynamic results have been re-
ported with small-sized prosthetic valves,11,12 there is
sufficient evidence that PPM is associated with increased
mortality, decreased exercise tolerance, and reduced LV
mass regression after AVR for aortic stenosis.13-16
Furthermore, it has been also shown that recipients of
a 19-mm St Jude Medical Inc (St Paul, Minn) aorticery c March 2014
TABLE 3. Echocardiographic data
Values Preoperative Discharge Follow-up
P
value
EF (%) 55  7 52  4 54  5 NS*
EDV (mL) 85  35 81  13 80  25 NS*
EDD (mm) 47  6 NA 45  6 NS*
IVS (mm) 12.3  1.4 12.1  0.8 10.8  1.2 <.05*
Aortic annulus (mm) 19.4  1.0 — —
Aortic root (mm) 27.6  2.5 29.9  2.7 31.1  3.7 <.001*
STJ (mm) 31.0  5.0 31.2  6.1 31.0  5.3 NS*
Vmax (m/s) 4.6  0.5 2.4  0.5 2.4  0.5 <.001y
PG (mm Hg) 91  20 25  10 24  10 <.001y
MG (mm Hg) 56  11 15  6 14  6 <.001y
iEOA — 0.91  0.23 0.88  0.20 NSz
EF, Ejection fraction; EDV, end-diastolic volume; EDD, end-diastolic diameter; IVS,
interventricular septum; STJ, sinotubular junction; Vmax, maximum velocity;
PG, peak gradient; MG, mean gradient; iEOA, indexed effective orifice area;
NA, not available; NS, not significant. *Follow-up versus preoperative and discharge.
yFollow-up and discharge versus preoperative. zFollow-up versus discharge.
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a higher rate of cardiac events at 15 years when compared
with 21-mm valves.17 Another study by our group demon-
strated that patients with a 21-mm aortic St Jude prosthesis
and BSA of 1.70m2 or greater showed a significant incidence
of PPM detected at cardiopulmonary exercise testing.18 On
the basis of these considerations in patients with a diminutive
aortic annulus, particularly in those with a large BSA, EAA
seems indicated to minimize PPM. Alterative techniques in-
clude the use of homografts, autografts, stentless valves, or
total aortic root replacement; however, most of these may
be time-consuming and cumbersome with intrinsic morbid-
ity, and therefore not too appealing to many surgeons.
The techniques of EAA were pioneered by Nicks and
colleagues2 in 1970 and subsequently reported by
others.3-5 A simplified technique was described by NunezFIGURE 2. A, Angio–computed tomography of a 61-year-old woman 12 years
located in the arch. B, Transverse section showing calcific deposits in the aorti
The Journal of Thoracic and Caand colleagues8 in 1983. EAA is performed as much as in
the description by Manouguian and Seybold-Epting5 by
prolonging the aortotomy to divide the commissure be-
tween the left and noncoronary cusps into the anterior mitral
leaflet, but without entering the left atrial roof and closing
the defect with a Dacron patch. We have adopted this tech-
nique, using at variance mostly a patch of bovine pericar-
dium, showing that it is simple and reproducible.6 In
a second series of 16 patients, there was no operative mor-
tality with stability of aortic diameters at 30 months of
follow-up, confirming the safety and effectiveness of this
technique in allowing adequate EAA.7 Large series of
EAA associated with AVR have been reported19-24 using
a variety of techniques and materials, such as autologous
or xenograft pericardium or synthetic patches, but reports
on long-term follow-up are limited. Piehler and associates19
reported on 96 patients undergoing EAAwith the technique
by Nicks and colleagues2 with autologous pericardium and
a maximum follow up of 15 years; 24 patients required re-
operation, and in all of them the pericardium was found to
bewell healed, not dilated but thickened and often calcified.
Kulik and colleagues23 reported their experience with 114
patients requiring EAA with the techniques by Nicks and
colleagues2 or Manouguian and Seybold-Epting5 using
both a patch of synthetic material or autologous pericar-
dium. At 10-year follow-up, they observed an actuarial sur-
vival of 69.7% and 86.4% of freedom from congestive
heart failure, data not significantly different from those hav-
ing AVR alone during the same period. In all other large
series reported long-term follow-up data are not avail-
able.20-22,24
We are the first to report an extended follow-up (up to 18
years) of patients having AVR and concomitant EAA. Fur-
thermore, we provide long-term data on the variations with
time of the aortic root dimensions both at the level of the si-
nuses of Valsalva and at the STJ assessed by echocardio-
graphic and ACT studies with the aim of verify stabilityafter operation showing normal aortic diameters with calcific spots mainly
c root corresponding to the site of the pericardial patch (arrow).
rdiovascular Surgery c Volume 147, Number 3 981
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We have shown that EAA can be performed with low mor-
tality and without significantly increasing operative times as
observed by others.21,22,24 EAA is an effective procedure
because it minimizes the occurrence of PPM. In our
series, severe PPM was never observed after EAA, and
only 2 patients presented with a moderate PPM. Mild
PPM is unavoidable after AVR even when associated with
EAA because of the intrinsic gradient of any implanted
stented mechanical or biological prosthesis; however,
mild PPM did not influence late patient outcome because
most of the late deaths were due to noncardiac causes.
Further findings of our study indicate that this procedure
was not associated with major postoperative
complications, in particular, no cases of paravalvular leak
or significant mitral regurgitation were observed.
Echocardiographic controls demonstrated stability of
aortic diameters with time, and such data were confirmed
by ACT controls performed in late survivors. No cases of
aneurysmal dilatation were observed. Although the patch
is inserted in a high-pressure environment, xenograft peri-
cardial tissue does not dilate and is not prone to late aneu-
rysm formation, most likely because of the limited size of
the patch or because it may shrink or even calcify with
time,25 as much as it occurs with autologous pericardium,19
thus representing a valid alternative to synthetic material.
Calcification of the aorta was observed in our ACT studies,
some of them corresponding to the site of the pericardial
patch insertion.
Study Limitations
The major limitation of this study is represented by its
retrospective nature, including a limited number of patients
albeit with a relatively uncommon procedure and a partially
incomplete follow-up; however, accurate evaluation of
long-term survivors with echocardiographic and ACT stud-
ies provided meaningful data to assess the effectiveness of
the procedure up to 18 years of follow-up. Our data demon-
strate that the technique we used, proposed by Nunez and
colleagues,8 is simple, allows a prosthesis 1 to 2 sizes larger
to be inserted, does not interfere with the function of the mi-
tral valve, and provides adequate relief of LV obstruction.
We also confirm that xenograft pericardium is a versatile
material for intracardiac applications, is extremely useful
for EAA because it allows adequate hemostatic sutures, is
strong enough to hold stitches, and does not tend to dilate
with time. As an alternative, autologous pericardium could
be used, but we found that bovine pericardium is stiffer but
still pliable enough and easy to work with.
CONCLUSIONS
EAA during AVR is a valid option in patients with
a small aortic annulus, and it should be strongly consid-
ered to prevent PPM and its deleterious long-term effects;982 The Journal of Thoracic and Cardiovascular Surghowever, considering the rather high mean age of patients
in this series, whether these conclusions may be applied
to young, active subjects must be verified by further
studies.
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